Back to search

Article

Acquired resistance to anti-PD1 therapy in patients with NSCLC reveals changes in T cell phenotypes and <i>MET</i> amplification

2022-04-10

Abstract excerpt

The treatment of non-small cell lung cancer (NSCLC) patients with immune checkpoint inhibitors has prolonged their survival dramatically. However, some patients develop resistance after initial response. Here, we used imaging mass cytometry and whole exome and RNA sequencing to analyze matching tumor samples from a cohort of NSCLC patients who initially responded to immune checkpoint inhibitor therapy and later de...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
c31ac848-4b0b-5743-8093-c797b4f88718
DOI
10.1101/2022.04.08.487590
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Acquired resistance to anti-PD1 therapy in patients with NSCLC reveals changes in T cell phenotypes and <i>MET</i> amplificationDOI 10.1101/2022.04.08.487590
Acquired resistance to anti-PD1 therapy in patients with NSCLC associates with immunosuppressive T cell phenotype.Semantic proximity
Clinical and molecular features of acquired resistance to immunotherapy in non-small cell lung cancerSemantic proximity
Clinical and molecular features of acquired resistance to immunotherapy in non-small cell lung cancerSemantic proximity
Pan-cancer analysis in the real-world setting uncovers immunogenomic drivers of acquired resistance post-immunotherapySemantic proximity
High-dimensional immune profiling of peripheral blood identifies immune correlates of anti-PD-1/PD-L1 resistance in oncogenic driver mutation-positive NSCLC.Semantic proximity
Persist or resist: Immune checkpoint inhibitors in EGFR ‐mutated NSCLCSemantic proximity
Predictive biomarkers and mechanisms underlying resistance to PD1/PD-L1 blockade cancer immunotherapySemantic proximity
Evolution of resistance to KRAS <sup>G12C</sup> inhibitor in a non-small cell lung cancer responderSemantic proximity
Efficacy and mechanisms of immune checkpoint inhibitors in late-stage EGFR-mutated non-small cell lung cancer following targeted therapy resistance.Semantic proximity
Unmasking PD-1 Resistance by Next-Generation SequencingSemantic proximity
Evolution of resistance to KRASG12C inhibitor in a non-small cell lung cancer responderSemantic proximity
Strong Programmed Death Ligand 1 Expression Predicts Poor Response and De Novo Resistance to EGFR Tyrosine Kinase Inhibitors Among NSCLC Patients With EGFR Mutation.Semantic proximity
Select a neighboring publication to make it the new centre.